How do initial signals of quality influence the diffusion of new medical products? the case of new cancer drug treatments

Advances in Health Economics and Health Services Research

Volumn 23, Issue , 2012, Pages 123-148

  Conti, Rena M ^a,b   Bernstein, Arielle ^a   Meltzer, David O ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

Cancer; Diffusion; Effectiveness; New technology; Prescription drugs

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; DASATINIB; ERLOTINIB; PEMETREXED; SORAFENIB; SUNITINIB;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BREAST CANCER; BRONCHUS CANCER; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER SURVIVAL; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; COLORECTAL CANCER; DIGESTIVE SYSTEM CANCER; DRUG APPROVAL; DRUG DIFFUSION; DRUG INDICATION; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MOUTH CANCER; PANCREAS CANCER; PHARYNX CANCER; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; SARCOMA; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; HUMAN; MASS COMMUNICATION; TREATMENT OUTCOME; UNITED STATES;

ANTINEOPLASTIC AGENTS; DIFFUSION OF INNOVATION; DISEASE-FREE SURVIVAL; DRUG APPROVAL; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME; UNITED STATES;

EID: 84872111068     PISSN: 07312199     EISSN: None     Source Type: Book Series    
DOI: 10.1108/S0731-2199(2012)0000023008     Document Type: Article

References (50)

1. Abrams, T. A., Brightly, R., Mao, J., Kirkner, G., Meyerhardt, J. A., Schrag, D., & Fuchs, C. S. (2011). Patterns of adjuvant chemotherapy use in a population based cohort of patients with resected Stage II or Stage III colon cancer. Journal of Clinical Oncology, 29(24), 3255-3262.
2. Ackerberg, D. (2003). Advertising, learning, and consumer choice in experience good markets: A structural examination. International Economics Review, 44, 1007-1040. (Pubitemid 37001801)
3. Aitken, M. L., Berndt, E. R., & Cutler, D. M. (2009). Prescription drug spending trends in the US: Looking beyond the turning point. Health Affairs, 28(1), w151-w160. Epub December 16, 2008.
4. American Society of Clinical Oncology. (2006). Reimbursement for cancer treatment: Coverage of off-label drug indications. Journal of Clinical Oncology, 24, 3206-3208.
5. Avorn, J., Chen, M., & Hartley, R. (1982). Scientific versus commercial sources of influence on the prescribing behavior of physicians. American Journal of Medicine, 73, 4-8. (Pubitemid 12048270)
6. Azoulay, P. (2002). Do pharmaceutical sales respond to scientific evidence? Journal of Economics Management and Strategy, 11, 551-594.
7. Azoulay, P., Berndt, E., & Pindyck, R. (2003). Network externalities and diffusion in pharmaceutical markets: Anti-ulcer drugs. Journal of Industrial Economics, 51, 243-270. (Pubitemid 36891502)
8. Berry, S. R., Bell, C. M., Ubel, P. A., Evans, W. K., Nadler, E., Strevel, E. L., & Neumann, P. J. (2010). Continental Divide? The attitudes of US and Canadian oncologists on the costs, cost-effectiveness, and health policies associated with new cancer drugs. Journal of Clinical Oncology, 28(27), 4149-4153.
9. Center for Medicare and Medicaid Services. (2008). Characteristics and perceptions of the medicare population sourcebook, Section 1. Retrieved from http://www.cms.gov/MCBS/DT/list.asp#TopOfPage. Accessed on February 2012.
10. Conti, R. M. (2003). Balancing safety, effectiveness and public desire: The FDA and cancer. The Commonwealth Fund, Issue Brief. 615.
11. Conti, R. M., Rosenthal, M. B., Polite, B., Bach, P., & Shih, Y.-C. T. (2012, May 1). Infused chemotherapy use in the elderly following patent expiration. American Journal of Management Care, 18(5), e173-e178.
12. Coscelli, A., & Shum, M. (2004). An empirical model of learning and patient spillovers in new drug entry. Journal of Econometrics, 122, 213-246.
13. Dranove, D., & Meltzer, D. O. (1994). Do important drugs reach the market sooner? RAND Journal of Economics, 25(3), 402-423.
14. Edwards, B. K., Brown, M. L., Wingo, P.A., Howe, H. L., Ward,E., Ries, L. A.,yPickle, L.W. (2005). Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. Journal of the National Cancer Institute, 97(19), 1407-1427. (Pubitemid 41520077)
15. Frank, R. G., & McGuire, T. G. (2000). Economics and mental health, In A. J. Culyer & J. P. Newhouse (Eds.), Handbook of health economics (1 ed., Vol. 1, Chapter 16, pp. 893-954). Amsterdam: Elsevier.
16. Freiman, M. P. (1985). The rate of diffusion of new procedures among physicians: The impact of specialty and practice characteristics. Medical Care, 23(8), 939-945. (Pubitemid 15000094)
17. Gandal, N., Kende, M., & Rob, R. (2000). The dynamics of technological diffusion in hardware/software systems: The case of compact disc players. RAND Journal of Health Economics, 31, 43-61.
18. Geroski, P. A. (2000). Models of technology diffusion. Research Policy, 29(4/5), 603-625.
19. Giordano, S. H. (2012, May 10). Radiotherapy in older women with low-risk breast cancer: Why did practice not change? Journal of Clinical Oncology, 30(14), 1577-1578. Epub March 5, 2012.
20. Griliches, Z. (1957). Hybrid corn: An exploration in the economics of technological change. Econometrica, 25, 501-522.
21. Hall, B. H., & Khan, B. (2003). Diffusion of new technology. In D. C. Jones (Ed.), New economy handbook. San Diego, CA: Academic Press.
22. Hannan, T., & McDowell, J. (1984a). The determinants of technology diffusion: The case of the banking firm. RAND Journal of Economics, 15(3), 328-335.
23. Harlan, L. C., Greene, A. L., Clegg, L. X., Mooney, M., Stevens, J. L., & Brown, M. L. (2005). Insurance status and the use of guideline therapy in the treatment of selected cancers. Journal of Clinical Oncology, 23(36), 9079-9088.
24. Jacobson, M., Earle, C. C., Price, M., & Newhouse, J. P. (2010). How Medicare's payment cuts for cancer chemotherapy drugs changed patterns of treatment. Health Affairs, 29(7), 1391-1399.
25. Jacobson, M., O'Malley, A. J., Earle, C. C., Pakes, J., Gaccione, P., & Newhouse, J. P. (2006). Does reimbursement influence chemotherapy treatment for cancer patients? Health Affairs, 25(2), 437-443. (Pubitemid 43529552)
26. Lyman, G. H. (2007). Economics of cancer care. Journal of Oncology Practice, 3, 113-114. (Pubitemid 351586741)
27. Mahajan, V., Muller, E., & Bass, F. (1995). Diffusion of new products: Empirical generalizations and managerial uses. Marketing Science, 14(3), G79-G88.
28. Mansfield, E. (1961). Technological change and the rate of imitation. Econometrics, 29(4), 741-766.
29. Meropol, N. J., & Schulman, K. A. (2007). Cost of cancer care: Issues and implications. Journal of Clinical Oncology, 25(2), 180-186. (Pubitemid 350003031)
30. Mille, D., Roy, T., Carre re, M. O., Ray, I., Ferdjaoui, N., Spath, H. M., y Philip, T. (2000). Economic impact of harmonizing medical practices: Compliance with clinical practice guidelines in the follow-up of breast cancer in a French Comprehensive Cancer Center. Journal of Clinical Oncology, 18(8), 1718-1724. (Pubitemid 30220550)
31. Nadler, E., Eckert, B., & Neumann, P. J. (2006). Do oncologists believe new cancer drugs offer good value? The Oncologist, 11, 90-95. (Pubitemid 43261756)
32. Neumann, P. J., Palmer, J. A., Nadler, E., Fang, C., & Ubel, P. (2010). Cancer therapy costs influence treatment: A national survey of oncologists. Health Affairs, 29(1), 196-202.
33. Newhouse, J. P. (1992). Medical care costs: How much welfare loss? Journal of Economic Perspectives, 6(3), 3-21.
34. Philipson, T. J., Becker, G., Goldman, D., & Murphy, K. M. (2010, January). Terminal care and the value of life near its end. NBER Working Paper No. 15649.
35. Ray-Coquard, I., Philip, T., de Laroche, G., Froger, X., Suchaud, J. P., Voloch, A., y Chauvin, F. (2002). A controlled ''before-after'' study: Impact of a clinical guidelines programme and regional cancer network organization on medical practice. British Journal of Cancer, 86(3), 313-321. (Pubitemid 34185109)
36. Scherer, F. M. (1993). Pricing, profits, and technological progress in the pharmaceutical industry. The Journal of Economic Perspectives, 7(3), 97-115.
37. Schrag, D. (2004). The price tag on progress - Chemotherapy for colorectal cancer. New England Journal of Medicine, 351(4), 317-319. (Pubitemid 38944397)
38. Shirvani, S. M., Pan, I. W., Buchholz, T. A., Shih, Y. C., Hoffman, K. E., Giordano, S. H., & Smith, B. D. (2011, Jun 27). Impact of evidence-based clinical guidelines on the adoption of postmastectomy radiation in older women. Cancer, 117(20), 4595-4605. doi: 10.1002/cncr.26081
39. Stoneman, P. (2001). The economics of technological diffusion. Oxford: Blackwells.
40. Strang, D., & Soule, S. A. (1998). Diffusion in organizations and social movements. Annual Review of Sociology, 24, 265-290.
41. Tamblyn, R., McLeod, P., Hanley, J. A., Girard, N., & Hurley, J. (2003). Physician and practice characteristics associated with the early utilization of new prescription drugs. Medical Care, 41(8), 895-908.
42. Tirole, J. (2000). The theory of industrial organization. Cambridge, MA: The MIT Press.
43. United States Food and Drug Administration. (2012). News Release: FDA Commissioner announces Avastin decision: Drug not shown to be safe and effective in breast cancer patients. Retrieved from http://www.fda.gov/NewsEvents/ Newsroom/PressAnnounce ments/ucm280536.htm. Accessed on January 2012.
44. United States National Institutes of Health. (2011). Retrieved from http://clinicaltrials.gov/ct2/search. Accessed on August 2011.
45. Urban, G. L., Carter, T., Gaskin, S., & Mucha, Z. (1996). Market share rewards to pioneering brands: An empirical analysis and strategic implications. Management Science, 32(6), 645-659.
46. Warner, K. E. (1974). The need for some innovative concepts of innovation: An examination of research on the diffusion of innovations. Policy Sciences, 5(4), 433-451.
47. Warner, K. E. (1977). Treatment decision making in catastrophic illness. Medical Care, 15(1), 19-31.
48. Wooldridge, J. M. (2006). Introductory econometrics: A modern approach (3rd ed.). Mason, OH: Thomson/South-Western.
49. Yabroff, K. R., Lamont, E. B., Mariotto, A., Warren, J. L., Topor, M., Meekins, A., & Brown, M. L. (2008). Cost of care for elderly cancer patients in the United States. Journal of the National Cancer Institute, 100(9), 630-641. Epub April 29, 2008.
50. Yin, W. (2008). Market incentives and pharmaceutical innovation. Journal of Health Economics, 27(4), 1060-1077.